Journal of Neuroscience and Neurodevelopmental Disorders (JNDD)

OLITES PUBLISHERS
A Global Approach For Research

Open Access

Review Article

Silent Degeneration: Unraveling the Clinical and Molecular Complexity of Amyotrophic Lateral Sclerosis

Creighton H, Brunner U, Zisserman F, Agounad D, Albuquerque W

Clinical Neuroscience MR Research Group, Hungary
***Corresponding Author:** Zisserman F, Clinical Neuroscience MR Research Group, Hungary
Citation: Zisserman F, Silent Degeneration: Unraveling the Clinical and Molecular Complexity of Amyotrophic Lateral Sclerosis V1(3),2025

Received date: December 15, 2025**: Accepted date:** December 20, 2025**: Published date:** December 30,2025

Keywords: genetic mutations, frontotemporal dementia, fasciculations, neuronal regeneration, targeted interventions

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor neurons, leading to muscle weakness, paralysis, and ultimately respiratory failure. Despite being relatively rare, ALS has profound clinical and social implications due to its rapid progression and lack of curative therapy. This article explores the epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, and current management strategies for ALS. Advances in molecular biology, including insights into genetic mutations such as SOD1 and C9orf72, have enhanced understanding of disease mechanisms but have yet to translate into definitive treatments. Multidisciplinary care remains the cornerstone of improving quality of life. Ongoing research into gene therapy, neuroprotection, and personalized medicine offers hope for future therapeutic breakthroughs.

Introduction

Amyotrophic Lateral Sclerosis, often referred to as Lou Gehrig's disease after the baseball player Lou Gehrig, is a fatal neurodegenerative condition that affects motor neurons responsible for voluntary muscle control. The disease leads to progressive muscle wasting and weakness while typically sparing cognitive function in early stages, although some patients develop frontotemporal dementia

Epidemiology

ALS has a global incidence of approximately 1–2 cases per 100,000 people annually. It commonly presents between the ages of 40 and 70 years, with a slight male predominance. About 90–95% of cases are sporadic, while 5–10% are familial, often linked to genetic mutations

Pathophysiology

The hallmark of ALS is degeneration of both upper motor neurons (in the motor cortex) and lower motor neurons (in the brainstem and spinal cord). Several mechanisms contribute to neuronal death:

- **Oxidative stress** due to mutations in genes like SOD1
- **Protein aggregation** (e.g., TDP-43 inclusions)
- **Glutamate excitotoxicity** leading to neuronal injury
- **Mitochondrial dysfunction**
- **Neuroinflammation** involving microglial activation

Mutations in genes such as C9orf72, TARDBP, and FUS have been strongly associated with familial ALS

Clinical Features

ALS presents with a combination of upper and lower motor neuron signs:

Early Symptoms:

- Muscle weakness (often asymmetric)
- Fasciculations (muscle twitching)
- Difficulty in fine motor tasks
- Slurred speech (bulbar involvement)

Progressive Symptoms:

- Spasticity and hyperreflexia

Journal of Neuroscience and Neurodevelopmental Disorders (JNDD)

- Muscle atrophy
- Dysphagia (difficulty swallowing)
- Respiratory muscle weakness

Despite severe physical decline, many patients remain cognitively intact, as famously demonstrated by physicist Stephen Hawking.

Diagnosis

There is no single definitive test for ALS. Diagnosis is primarily clinical and supported by investigations:

- **Electromyography (EMG):** Detects denervation
- **Nerve conduction studies:** Rule out other neuropathies
- **MRI:** Excludes structural lesions
- **Genetic testing:** In familial cases

The El Escorial criteria are commonly used to establish diagnosis.

Management

Currently, there is no cure for ALS, but treatment focuses on slowing disease progression and improving quality of life.

Pharmacological Treatment:

- Riluzole: Modestly prolongs survival
- Edaravone: May slow functional decline

Supportive Care:

- Physical therapy
- Nutritional support (feeding tubes if necessary)
- Non-invasive ventilation for respiratory support
- Speech therapy

A multidisciplinary approach significantly enhances patient outcomes.

Prognosis

The average survival time after diagnosis is 3–5 years, although some individuals live longer. Death usually results from respiratory failure.

Recent Advances and Future Directions

Research into ALS is rapidly evolving:

- **Gene therapy** targeting SOD1 mutations
- **Stem cell therapy** for neuronal regeneration
- **Biomarkers** for early detection
- **Precision medicine** approaches based on genetic profiling

These innovations hold promise for altering the disease course in the future

Conclusion

Amyotrophic Lateral Sclerosis remains one of the most challenging neurodegenerative disorders due to its complex etiology and lack of effective curative treatments. While current therapies focus on symptom management, advances in molecular research are paving the way for targeted interventions. Continued research and collaborative care are essential to improve survival and quality of life for affected individuals.

References

1. Renaud, L.; Picher-Martel, V.; Codron, P.; Julien, J.-P. Key Role of UBQLN2 in Pathogenesis of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Acta Neuropathol. Commun. 2019, 7, 103.
2. Daoud, H.; Dobrzeniecka, S.; Camu, W.; Meininger, V.; Dupré, N.; Dion, P.A.; Rouleau, G.A. Mutation Analysis of PFN1 in Familial Amyotrophic Lateral Sclerosis Patients. Neurobiol. Aging 2013, 34, 1311.e1–1311.e2
3. Guo, W.; Naujock, M.; Fumagalli, L.; Vandoorne, T.; Baatsen, P.; Boon, R.; Ordovás, L.; Patel, A.; Welters, M.; Vanwelden, T.; et al. HDAC6 Inhibition Reverses Axonal Transport Defects in Motor Neurons Derived from FUS-ALS Patients. Nat. Commun. 2017, 8, 861.
4. Dwivedi, J.; Kaushal, S.; Jeslin, D.; Karpagavalli, L.; Kumar, R.; Dev, D.; Wal, P. Gene Augmentation Techniques to Stimulate Wound Healing Process: Progress and Prospects. Curr. Gene Ther. 2024, 25, 1–23.
5. Weng, T.-Y.; Tsai, S.-Y.A.; Su, T.-P. Roles of Sigma-1 Receptors on Mitochondrial Functions Relevant to Neurodegenerative Diseases. J. Biomed. Sci. 2017, 24, 74.
6. Shefner, J.M.; Oskarsson, B.; Macklin, E.A.; Chibnik, L.B.; Quintana, M.; Saville, B.R.; Detry, M.A.; Vestrucci, M.; Marion, J.; Mcglothlin, A.; et al. Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial. JAMA 2025, 333, 1128–1137.
7. Urani, A.; Romieu, P.; Roman, F.J.; Yamada, K.; Noda, Y.; Kamei, H.; Manh Tran, H.; Nagai, T.; Nabeshima, T.; Maurice, T. Enhanced Antidepressant Efficacy of Σ1 Receptor

Journal of Neuroscience and Neurodevelopmental Disorders (JNDD)

Agonists in Rats after Chronic Intracerebroventricular Infusion of β-Amyloid-(1–40) Protein. Eur. J. Pharmacol. 2004, 486, 151–161.

.

Journal of Neuroscience and Neurodevelopmental Disorders (JNDD)